D-0389-2024 Class III Terminated
FDA drug recall D-0389-2024 was initiated by Novitium Pharma LLC on Mar 4, 2024 and is designated Class III. Reason for recall: Cross Contamination with Other Products:(mycophenolate mofetil). The recall status is terminated (terminated Mar 21, 2025). Affected quantity: 3,940 1000-count bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 27, 2024
- Initiation Date
- Mar 4, 2024
- Termination Date
- Mar 21, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 3,940 1000-count bottles
Product description
Digoxin Tablets, USP 125mcg, (0.125 mg), 1000-count bottle, Rx Only, Manufactured by: Novitium Pharma LLC., 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-201-20
Reason for recall
Cross Contamination with Other Products:(mycophenolate mofetil).
Distribution pattern
Nationwide in the USA
Code information
Lot #: M23172A, Exp 01/31/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0389-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026